TSE:BHC Stock Gets Stronger EPS Forecast from Zacks Research

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research raised their Q3 2028 EPS estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, September 22nd. Zacks Research analyst Team now forecasts that the company will post earnings of $1.14 per share for the quarter, up from their previous estimate of $1.13. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share.

Separately, Jefferies Financial Group upgraded Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

Bausch Health Companies Stock Performance

Shares of TSE:BHC opened at C$8.13 on Friday. The company’s 50 day simple moving average is C$8.50 and its 200 day simple moving average is C$7.69. The stock has a market capitalization of C$3.04 billion, a price-to-earnings ratio of -2.77, a price-to-earnings-growth ratio of 0.21 and a beta of 0.71. The company has a debt-to-equity ratio of -1,173.29, a current ratio of 1.44 and a quick ratio of 0.58. Bausch Health Companies has a 1 year low of C$6.10 and a 1 year high of C$11.08.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share for the quarter. The company had revenue of C$4.05 billion during the quarter. Bausch Health Companies had a negative net margin of 12.02% and a positive return on equity of 87.57%.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.